“Frontier Pharma: Dermatology Intracellular Signal Transducers And Cytokine Signaling Molecules Dominate Pipeline And First-in-Class Innovation” states that four of the five market-driving drugs – Cosentyx, Otezla, Eucrisa and Taltz – were approved for psoriasis, and one, Dupixent, became the first and only biologic to be approved for the treatment of atopic dermatitis. Indeed, Dupixent is expected to face very little competition and as a result will generate the second highest revenue of any drug in the therapy area. —
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare autoimmune disorders such as scleroderma, to very common conditions such as acne vulgaris and atopic dermatitis. For the past decade the majority of the therapeutic dermatology market has been saturated and highly genericized, and strongly dominated by small molecules. There is a significant unmet need for more efficacious and safer treatment options, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues with the long-term use of many available treatments.
Order a copy of this research at https://www.marketinsightsreports.com/report/purchase/07055830?mode=su
Although the scope of dermatological disorders is diverse in terms of severity, clinical presentation, and key patient demographics, there is a degree of crossover between many indications in terms of their underlying pathophysiology. Increased inflammation and aberrant immune response resulting in skin barrier dysfunction are commonly shared causes. Infections and dysfunctions in wound healing are also common causes of dermatological diseases.
Scientific advancements over the course of recent decades have revealed a broad range of novel potential molecular targets, enabling the advancement of a previously stagnant field. This is reflected in the high number of products being developed, with 961 pipeline products currently in the dermatology therapy area pipeline.
Analysis indicates that the current pipeline is following a trend of focusing on innovative biologic therapies, following the clinical and commercial success of such therapies in the treatment of psoriasis. There are various biologics in the pipeline for major skin disorders - including atopic dermatitis, acne vulgaris and rosacea - for which there is a significant unmet need in patients with moderate-to-severe conditions.
Moreover, there is a considerable degree of innovation present in the therapy area, as there are a total of 197 first-in-class pipeline products in development for dermatological indications, representing 32% of the 617 pipeline products for which there is a disclosed molecular target. Many of these appear promising in terms of safety and efficacy, and carry a significant potential to strengthen the treatment landscape for various dermatological conditions.
Complete research report of 98 pages with List of Tables and Figures is available at https://www.marketinsightsreports.com/reports/07055830/frontier-pharma-dermatology-intracellular-signal-transducers-and-cytokine-signaling-molecules-dominate-pipeline-and-first-in-class-innovation
Scope of this report:
With 961 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future dermatology market? There are 197 first-in-class products in the dermatology pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target? The majority of first-in-class products are in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class? A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?
This report will assist you to:-
• Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
• Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
• Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
• Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.
Name: Diane Conrad
Email: Send Email
Organization: Market Insights Reports
Release ID: 214531